The Business Of Biotech Podcast

EPISODES

Episode 5: Finding Funding In Volatile Times With Ben Zeskind

Monday, June 1, 2020

This week's Business Of Biotech pod features Immuneering CEO Dr. Ben Zeskind, who launched his biotech on the back of creative financing in the throes of the Great Recession. A pivot into biopharma at the outset of the COVID-19 pandemic landed Immuneering a $20 million series A round to develop its pipeline.  Continue Reading..

• Episode 4: Building Your Pitch With Leslie Williams

  Leslie Williams is a multi-time biotech founder and board member who's honed her pitch-building skills to a fine point. On this episode of The Business Of Biotech, Williams shares best practices for building your pitch deck, how to draw out the nuance that makes your story unique, what to expect in your initial pitch session and follow-on meetings, and why the human element trumps everything else in an otherwise formulaic pitch process.

• Episode 3: The Biopharma Exit Strategy With Dr. Francois Nader

  On this episode of The Business Of Biotech, we talk with Dr. Francois Nader—a man who's orchestrated several wildly successful biotech exits—about why it's imperative to begin with the end in mind as you create value for stakeholders, and how to navigate your options when the time to exit is right.

• Episode 2: The Business Of Biotech: Allan Shaw

  Few are better suited to advise emerging biopharma leaders on the building blocks of biotech than Allan Shaw. On this episode of The Business Of Biotech, we'll absorb Shaw's to-the-point, practical advice on winning finances, building a pitch, assembling a biotech all-star team, leaving the incubator, navigating early regulatory considerations, and more. 

• Episode 1: Introducing The Business Of Biotech Podcast

  With the support of Cytiva, formerly GE Healthcare Life Sciences, we're launching a podcast to serve as a resource for the leaders of new and emerging biopharmas. We have an incredible group of guests—all of them founders who have taken biotherapy ideas and successfully turned them into clinical realities—lined up to share their insight with you. Here’s how the series, which is focused on the financial, organizational, HR, process, and regulatory aspects of launching a biopharma company, will play out.